Prezista Related Clinical Trials
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients [Completed]
GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men. [Active, not recruiting]
TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced HIV-1 Infected Patients, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV. [Completed]
A Pediatric Trial to Provide Dose Recommendation of TMC114/Rtv in HIV-1 Infected Children and Adolescents [Active, not recruiting]
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously [Terminated]
A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes, and Eliminates a Drug), of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Nave HIV-1 Patients (Patients Have Never Received ARV Treatment). [Active, not recruiting]
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications. [Active, not recruiting]
TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options [Completed]
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients [Active, not recruiting]
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-Experienced Subjects. [Active, not recruiting]
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects. [Recruiting]
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With TMC114r (Ritonavir), and TMC125 (Etravirine) in HIV-1 Infected Pregnant Women [Recruiting]
Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients [Recruiting]
TMC114-TiDP31-C229: This is a Study on the Effectiveness, Safety and Tolerability of Darunavir (DRV), Administered With Low-Dose Ritonavir (Rtv) as 800/100 mg Daily Versus 600/100 mg Twice Per Day for HIV-1 Patients Over a 48-Week Treatment Period. [Recruiting]
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue [Not yet recruiting]
Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir, Etravirine and MK-0518 in HIV Patients With Resistant Viruses [Active, not recruiting]
Genetic Predictors of Variability in the Drug-Drug Interaction Between Darunavir/Ritonavir and Pravastatin [Recruiting]
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-Infected Patients That Have Never Received Treatment. [Recruiting]
TMC114-TiDP29-C228 - A Safety Study to Evaluate the Antiviral Activity of Darunavir (DRV) in Combination With Ritonavir (Rtv) in HIV 1 Infected Children From 3 Years to Below 6 Years of Age [Not yet recruiting]
TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers. [Recruiting]
Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-Boosted Protease Inhibitors [Recruiting]
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir [Recruiting]
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 [Not yet recruiting]
TMC114-TiDP29-C230 - A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Adolescents Between 12 and 18 Years of Age Who Have Not Received Previous Treatment With Antiretroviral Drugs [Recruiting]
Double Protease Inhibitor to Darunavir Switch Study [Active, not recruiting]
Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy [Recruiting]
Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected Antiretroviral Naïve Patients Treated With Darunavir/Ritonavir and Etravirine [Not yet recruiting]
Abacavir Pharmacokinetic Study [Recruiting]
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients [Recruiting]
A Double-Blind, Placebo-Controlled, Crossover, Dose Escalating Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects [Recruiting]
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection. [Recruiting]
Standard Antiretroviral v. Multi-Class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) [Recruiting]
Safety and Effectiveness of Raltegravir and Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults [Not yet recruiting]
Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens [Not yet recruiting]
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1 [Recruiting]
Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r [Recruiting]
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI [Recruiting]
NNRTI/PI Toxicity Switch to Darunivir Study. [Recruiting]
GSK1349572 Drug Interaction Study With Protease Inhibitors [Recruiting]
Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV [Recruiting]
Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults [Not yet recruiting]
Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications [Recruiting]
Evaluation of Three Strategies of Second-Line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) [Not yet recruiting]
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-Selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options. [Active, not recruiting]
TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-Selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options. [Active, not recruiting]
Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study [Recruiting]
An Open-Label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216). [Recruiting]
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children [Recruiting]
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients [Recruiting]
Optimizing Treatment for Treatment-Experienced, HIV-infected People [Recruiting]
Comparative Study of Three NNRTI-Sparing HAART Regimens [Not yet recruiting]
Clinical Trial of CNS-Targeted HAART (CIT2) [Recruiting]
|
